Piramal to acquire 100% Stake in Hemmo Pharmaceuticals

1 April 2021
pirama_large_2021

Piramal Pharma Limited’s (BSE: 500302; PPL) contract development and manufacturing organization (CDMO), Piramal Pharma Solutions (PPS), has entered into an agreement to acquire a 100% stake in fellow India-based Hemmo Pharmaceuticals.

The accord provides for an upfront consideration of 7.75 billion rupees ($105.6 million) and earn-outs linked to achievement of milestones.

As PPS continues to expand and grow its capabilities and position as a leading CDMO, this acquisition marks PPS’ foray into the development and manufacturing of peptide active pharmaceutical ingredients (APIs), a capability that complements PPS’ existing service offering.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics